Ready to invest?
Open a free brokerage account and start building your portfolio today.
Open a free brokerage account and start building your portfolio today.
PLRX
$1.28
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designa...
View full profileConnect your bank account to understand your spending habits and explore hypothetical growth scenarios. For educational purposes only — not investment advice.
Educational illustration: hypothetical DCA into Pliant Therapeutics Inc (PLRX) over the past year. This is not a recommendation to buy this security.
Total Invested
$1,400
14 months
Worth Today
$1,281
at current price
Loss
-$119
-8.5% return
Hypothetical illustration using historical prices. This is for educational purposes only and is not investment advice. Past performance does not guarantee future results. Nuvestan is not a registered investment adviser. Consult a financial professional before making investment decisions.